We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
-18.23%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$428M
AUM Growth
-$179M
Cap. Flow
-$76.2M
Cap. Flow %
-17.79%
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
–
Reduced
5
Closed
–

Top Buys

Rank Stock Value
1
RGNX icon
Regenxbio
RGNX
+$1.98M

Top Sells

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$26.9M
2
TXG icon
10x Genomics
TXG
+$19.5M
3
INSM icon
Insmed
INSM
+$15.3M
4
XLRN
Acceleron Pharma
XLRN
+$12M
5
EPZM
Epizyme, Inc
EPZM
+$4.54M

Sector Composition

Rank Sector Weight
1 Healthcare 99.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXG icon
1
10x Genomics
TXG
$5.49B
$411M 95.85%
6,587,253
-250,000
-4% -$19.5M
EPZM
2
DELISTED
Epizyme, Inc
EPZM
$5.89M 1.38%
379,981
-211,323
-36% -$4.54M
INSM icon
3
Insmed
INSM
$23.2B
$3.79M 0.89%
236,547
-643,469
-73% -$15.3M
AERI
4
DELISTED
Aerie Pharmaceuticals
AERI
$3.42M 0.8%
253,698
-1,419,016
-85% -$26.9M
XLRN
5
DELISTED
Acceleron Pharma
XLRN
$3.13M 0.73%
34,784
-153,818
-82% -$12M
RGNX icon
6
Regenxbio
RGNX
$557M
$1.54M 0.36%
+47,443
New +$1.98M

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q1 2020 Portfolio in Review

As of Q1 2020, Foresite Capital Management II held 6 positions worth $428M, down 29% from $607M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management II withdrew a net $76.2M in Q1 2020, reducing 5 holdings. Its largest reduction was Aerie Pharmaceuticals, cutting an estimated $26.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 93% a quarter earlier.

Against the trend, Foresite Capital Management II opened a new position in Regenxbio worth $1.54M.

  • Foresite Capital Management II's largest Q1 2020 buy was Regenxbio: 47,443 shares worth $1.54M.
  • Foresite Capital Management II's biggest Q1 2020 reduction was Aerie Pharmaceuticals, cutting an estimated $26.9M.
  • Foresite Capital Management II's ten largest holdings make up 100% of its $428M portfolio in Q1 2020.
  • Foresite Capital Management II opened 1 new position and closed 0 in Q1 2020.
  • Foresite Capital Management II's portfolio value fell 29% quarter-over-quarter to $428M.

Based on Foresite Capital Management II's 13F filing for Q1 2020, filed 14 May 2020.